Press release - 28/06/2011 Ulcerative colitis: Lipid Therapeutics announces start of Phase IIb clinical trial Lipid Therapeutics, a biotechnology company, announced today that it has initiated a Phase IIb clinical trial with its lead product LT-02 in patients with ulcerative colitis. Lipid Therapeutics received approval for this multi-center, international trial from the authorities in Germany and Lithuania and is awaiting approval in Romania. Patient enrollment has already started in Germany and Lithuania.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ulcerative-colitis-lipid-therapeutics-announces-start-of-phase-iib-clinical-trial
Press release - 20/06/2011 CureVac presents new data for prostate and lung cancer vaccines CureVac GmbH presented promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO Conference in Chicago. Final trial results confirm safety and excellent antigen-specific immunogenicity of prostate cancer vaccine CV9103. And initial promising data from phase I/IIa trial of lung cancer vaccine CV9201 further supports the potential of CureVac’s RNActive® vaccination technology in cancer immunotherapy and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-presents-new-data-for-prostate-and-lung-cancer-vaccines
Press release - 15/06/2011 immatics’ pivotal Phase III trial with IMA901: First patients with renal cell carcinoma are vaccinated immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company’s lead cancer vaccine for the treatment of renal cell carcinoma (RCC).https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-pivotal-phase-iii-trial-with-ima901-first-patients-with-renal-cell-carcinoma-are-vaccinated
Article - 30/05/2011 From bench to bedside to bench The term translational medicine does not always refer to the concept “from bench to bedside and back”, and indeed is often used to refer to many other, somewhat distant, concepts. However, the new translation centres and translational research consortia do correspond to the original meaning. These new centres and consortia have become effective structures in health research in Germany whose goal is the continuous improvement of the diagnostic and…https://www.gesundheitsindustrie-bw.de/en/article/news/from-bench-to-bedside-to-bench
Article - 30/05/2011 Technology Licensing Office (TLB): invention and patent management The Technology Licensing Office TLB works in partnership with science and industry and is continuously coming up with new ways to ensure the economic success of inventions from all the key fields of technology. Dr. Frank Schlotter head of Life Sciences at the Karlsruhe-based TLB provides insights into the work that his office does taking as examples innovations from the fields of regenerative medicine and diagnostics.https://www.gesundheitsindustrie-bw.de/en/article/news/technology-licensing-office-tlb-invention-and-patent-management
Press release - 26/05/2011 High Scientific Level at the Second International Workshop about Drug-Drug Interactions The organisation team of the Second International DDI drug-drug interactions Workshop has expressed great satisfaction with the course of the scientific meeting. Thus the DDI Workshop at Marbach Castle is on its way to become an established platform for the annual exchange between experts scientists members of the industry and regulatory bodies regarding DDI affairs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-scientific-level-at-the-second-international-workshop-about-drug-drug-interactions
Press release - 19/05/2011 Curetis AG successfully increases Series A financing round to EUR 24.5 million Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced an extension of its Series A financing, bringing the total size of the round to € 24.5 million. CD-Venture joined the funding as a new investor, while all of Curetis' existing VC investors participated in the round. Several private investors also continued to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-successfully-increases-series-a-financing-round-to-eur-24-5-million
Press release - 23/04/2011 Liver cell infusion performed for first time in the United States on child with life-threatening disorder The liver cell infusion developed by the Weinheim-based biotechnology company Cytonet GmbH & Co. KG has been granted orphan drug status in the USA. The first American child suffering from urea cycle disorder (UCD) was treated with Cytonet’s liver cell infusion in a clinical trial that began in autumn 2010.https://www.gesundheitsindustrie-bw.de/en/article/press-release/liver-cell-infusion-performed-for-first-time-in-the-united-states-on-child-with-life-threatening-dis
Press release - 22/03/2011 Bringing artifical vision clinical trials to US Retina Implant AG Partners with Wills Eye Institute to Bring Artificial Vision Clinical Trials to the United States. Wills Eye to be the Primary Investigation Site to Offer the Subretinal Approach to Retinitis Pigmentosa Patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/bringing-artifical-vision-clinical-trials-to-us
Article - 21/03/2011 Immunotherapy: the rocky road to clinical application Hans-Georg Rammensee has one major goal: he wants to contribute to the successful application of immunotherapy in clinical settings and is convinced that this will only be possible once individualised immunotherapies are used. Individualised immunotherapy refers to the induction of a specific immune response against specific tumour-associated antigens. Rammensee has made major progress in this area and is now focused on overcoming the obstacles…https://www.gesundheitsindustrie-bw.de/en/article/news/immunotherapy-the-rocky-road-to-clinical-application
Press release - 13/03/2011 Vascular stent that dissolves on its own The first ever implant in Germany of a bioresorbable, drug-coated stent in a cardiac patient has been carried out by physicians from the University of Heidelberg. In contrast to traditional metal stents, which remain permanently in the patients’ body, the innovative implant dissolves around two years after the procedure is carried out.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vascular-stent-that-dissolves-on-its-own
Article - 14/02/2011 Affimed’s novel TandAb® antibodies enter clinical development phase With the initiation in October 2010 of a Phase I (“first in man”) study of the tetravalent, bispecific antibody AFM13 based on its proprietary TandAb® technology, Heidelberg-based Affimed Therapeutics AG has become a clinical drug development company. https://www.gesundheitsindustrie-bw.de/en/article/news/affimed-s-novel-tandab-antibodies-enter-clinical-development-phase
Dossier - 07/02/2011 The era of personalised medicine is dawning A promising future does not easily disappear into thin air. This is certainly the case with the vision of personalised medicine. For many years, biomedical researchers have vaunted the potential benefits of their findings despite the fact that neutral observers do not think that personalised medicine will really take off within the next 15 or 20 years. Moreover personalised medicine is a controversial term. So what is the state of play right now?https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-era-of-personalised-medicine-is-dawning
Press release - 24/01/2011 Synimmune - Close cooperation cuts new cancer drug development time A development project from Synimmune GmbH, founded in July 2010, made a big impression on the panel of assessors at the German Federal Ministry of Education and Research (BMBF). So much so, that the company was awarded EUR 2.5 million as part of the GO-Bio biotechnology start-up scheme. https://www.gesundheitsindustrie-bw.de/en/article/press-release/synimmune-close-cooperation-cuts-new-cancer-drug-development-time
Article - 12/12/2010 Pharmacovigilance: safety becomes a principle Tübingen-based CenTrial GmbH established in 2000 is a provider and manager of clinical trials. Pharmacovigilance is an important segment of the companys work CenTrial supports its clinical trial clients in all phases of clinical drug development related to drug safety up until the time a drug enters the market and beyond. The services offered range from the analysis of data to the complete design of the safety management process including…https://www.gesundheitsindustrie-bw.de/en/article/news/pharmacovigilance-safety-becomes-a-principle
Press release - 06/12/2010 Kihara Foundation Kihara Memorial Yokohama Foundation for the Advancement of Life Sciences called Kihara Foundation was established in 1985 in memory of the late Dr. Hiroshi Kihara a world famous geneticist and evolutionary scientist Professor of Kyoto University for the advancement of Life Sciences.https://www.gesundheitsindustrie-bw.de/en/article/press-release/kihara-foundation
Article - 30/11/2010 Off-label use in children: the problem is known but improvement happens step by slow step The majority of drugs prescribed to children and adolescents have not been specifically licensed for their use. The majority of drugs have been tested and formulated for adults. This so-called off-label practice is associated with greater risks than those one would expect in medicinal therapy. We talked to Michael Kölch senior consultant in the Department of Paediatric and Adolescent PsychiatryPsychotherapy at Ulm University Hospital about this…https://www.gesundheitsindustrie-bw.de/en/article/news/off-label-use-in-children-the-problem-is-known-but-improvement-happens-step-by-slow-step
Article - 29/11/2010 Adverse skin reactions - more than just skin deep Severe skin reactions such as toxic epidermal necrolysis TEN and Stevens-Johnson syndrome SJS are caused by drugs that have originally been developed for the treatment or alleviation of other diseases. In some cases the consumption of these drugs can be fatal. The Centre for Documentation of Severe Skin Reactions dZh in Freiburg has been collecting information on rare skin diseases for around 20 years.https://www.gesundheitsindustrie-bw.de/en/article/news/adverse-skin-reactions-more-than-just-skin-deep
Article - 22/11/2010 LEUKONET provides evidence for new therapies for CNS diseases The concept of evidence-based medicine stipulates that the efficacy of any therapy must be shown in large clinical studies before being used for treating patients. However this is a requirement that cannot be realistically fulfilled for rare diseases due to the small number of people affected. To redress this situation in the case of leukodystrophies rare metabolic disorders of the nervous system that affect only a small number of people in…https://www.gesundheitsindustrie-bw.de/en/article/news/leukonet-provides-evidence-for-new-therapies-for-cns-diseases
Press release - 19/11/2010 Affimed enrols first patients in Phase I Hodgkin’s lymphoma study The Heidelberg-based biotech company Affimed Therapeutics AG announced on 15th November 2010 that the first Hodgkin’s lymphoma patients have been treated with the AFM13 TandAb® antibody in a Phase I clinical study. Thus, the “first-in-man” tetravalent, bispecific antibody based on the company’s proprietary RECRUIT-TandAb® antibody technology has entered the clinic.https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-enrols-first-patients-in-phase-i-hodgkin-s-lymphoma-study
Article - 13/11/2010 Franz Porzsolt is turning existing beliefs and dogmas on their head Porzsolt a 64-year-old clinical economist specialist in internal medicine and oncologist enjoys turning accepted truths on their head. Many colleagues regard him as an outspoken critic of others for his tendency to refer to science as theory and clinical settings as practice. Porzsolt criticises evidence-based medicine as it is currently understood and applied.https://www.gesundheitsindustrie-bw.de/en/article/news/franz-porzsolt-is-turning-existing-beliefs-and-dogmas-on-their-head
Article - 18/10/2010 Maurits Ortmanns: visual prosthesis research benefits from microelectronics research in Ulm “Around one third of all visual prosthesis research in Germany is done by the Institute of Microelectronics at Ulm University,” said Maurits Ortmanns, a young electrical engineer who has been head of the Institute of Microelectronics since 2008. He is responsible for half of this figure and his colleague Albrecht Rothermel for the other half. The two engineers work for two German manufacturers who are developing competing versions of retinal…https://www.gesundheitsindustrie-bw.de/en/article/news/maurits-ortmanns-visual-prosthesis-research-benefits-from-microelectronics-research-in-ulm
Article - 30/08/2010 Bodensee Brustzentrum offers effective breast cancer prevention services The two Brustzentrum Bodensee (Lake Constance Breast Centre) sites at the Hospital in Constance and the Women’s Hospital in Friedrichshafen have a principal goal: to enable the best possible early detection of all types of breast cancer, to reduce the morbidity and mortality of breast cancer patients and to increase survival rates by offering ultra-modern breast cancer prevention measures. https://www.gesundheitsindustrie-bw.de/en/article/news/bodensee-brustzentrum-offers-effective-breast-cancer-prevention-services
Article - 30/08/2010 More effective prevention and treatment of diabetic feet Dr. med. dent. Hans-Helmut Schmidt has developed a device that enables the effective and hygienic treatment of patients with diabetic foot syndrome DFS. The new device known as DIAPEDES enables diabetic feet to be treated in a closed foot-shaped container under definite clinical conditions. Diabetic feet can smell and look quite unpleasant and the preventive care that this device will offer for many users has been developed with this problem in…https://www.gesundheitsindustrie-bw.de/en/article/news/more-effective-prevention-and-treatment-of-diabetic-feet
Press release - 12/08/2010 Glycotope Received Regulatory Approval for Glycooptimized and Fully Human Glycosylated Antibody CetuGEX™ and Enrolls First Patients in Clinical Trial Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX™ (GT-MAB 5.2-GEX) for the treatment of various solid cancers. https://www.gesundheitsindustrie-bw.de/en/article/press-release/glycotope-received-regulatory-approval-for-glycooptimized-and-fully-human-glycosylated-antibody-cetu